Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÀÎü ´ëÀå¾Ï ¼¼Æ÷ÁÖ(HT-29)¿¡¼­ ´ãÁó»ê ÇÕ¼ºÀ¯µµÃ¼(HS-1200)ÀÇ ¼¼Æ÷ »ç¸Á ±âÀü A Novel Chenodeoxycholic Derivative HS-1200 Induces Apoptosis in Human HT-29 Colon Cancer Cells

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2002³â 20±Ç 4È£ p.367 ~ 374
¼Ò¼Ó »ó¼¼Á¤º¸
¿À½Å±Ù/Sin Geun Oh ¾ç±¤¸ð/Çã¿øÁÖ/À¯¿µÇö/¼­È«¼®/ÀÌÇü½Ä/Kwang Mo Yang/Won Joo Hur/Young Hyun Yoo/Hong Suk Suh/Hyung Sik Lee

Abstract

¸ñÀû: ÀÎü ´ëÀå¾Ï ¼¼Æ÷ÁÖÀÎ HT-29¿¡ »õ·Î¿î CDCA ÇÕ¼ºÀ¯µµÃ¼ÀÎ HS-1200À» óġÇÏ¿© ¾Ï¼¼Æ÷ÀÇ Áõ½Ä¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú ¾ÆÆ÷Åä½Ã½º À¯µµ È°¼ºÀ» °üÂûÇÏ°í ±âÀüÀ» ¿¬±¸ÇÏ°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: Áö¼öÁõ½Ä±âÀÇ HT-29 ¼¼Æ÷¿¡ ´Ù¾çÇÑ ³óµµÀÇ CDCA ÇÕ¼ºÀ¯µµÃ¼ÀÎ HS-1200À» Åõ¾àÇÏ¿© IC50¸¦ ±¸ÇÏ¿´´Ù. IC50ÀÇ ³óµµ¸¦ ÂüÁ¶ÇÏ¿©, ¼¼Æ÷ »ýÁ¸´ÉÀÇ ½ÇÇèÀº trypan blue exclusion assay¸¦ ÀÌ¿ëÇÏ¿´°í, ¾ÆÆ÷Åä½Ã½º À¯µµ¿¡ °üÇÑ
°üÂû
½ÇÇèÀº agarose gel electrophoresis, TUNEL assay ¹× Hoechst stainingÀ» ÀÌ¿ëÇÏ¿´´Ù. Western blottingÀ» ÅëÇÑ PARP [poly (ADP-ribose) polymerase], caspase-3 ¹× DFF (DNA fragmentation factor)ÀÇ degradation ¹× cleavage µîÀ» °üÂûÇÏ¿´´Ù.
Immunofluorescent
method¸¦ ÅëÇÑ cytochrome c ¹æÃâ ÃøÁ¤ ¹× ¹ÌÅäÄܵ帮¾Æ ¸·ÀüÀ§ ÃøÁ¤À» ½Ç½ÃÇÏ¿´´Ù.

°á°ú: HS-1200Àº agarose gel electrophoresis ½ÇÇè¿¡¼­ DNA ladderÀÇ °üÂû, TUNEL assay ¹× Hoechst staining ¿¡¼­ ¾ÆÆ÷Åä½Ã½º ¼¼Æ÷µéÀÌ ´ë·®À¸·Î °üÂûµÇ´Â °á°ú·Î ¹Ì·ç¾î ¾ÆÆ÷Åä½Ã½º¿¡ ÀÇÇÑ ¼¼Æ÷ »ç¸ÁÀ» À¯µµÇÏ´Â °ÍÀ¸·Î »ç·áµÇ¾ú´Ù. ¾ÆÆ÷Åä½Ã½º¿¡ ÀÇÇÑ
¼¼Æ÷
»ç¸ÁÀ» °ËÁõÇϱâ À§ÇÑ Western blottingÀ» ÅëÇÑ PARP cleavage, caspase-3 ¹× DFF ¹ßÇö °üÂû¿¡¼­ °øÈ÷ HS-1200 óġ ÈÄ 4½Ã°£ °ºÎÅÍ PARP, caspase-3 ¹× DFFÀÇ degradation ¹× cleavage°¡ °üÂûµÇ¾ú´Ù. HS-1200ÀÇ ¾ÆÆ÷Åä½Ã½º À¯µµ¿¡ À̸£´Â ±âÀü¿¬±¸¿¡¼­
¹ÌÅäÄܵ帮¾ÆÀÇ
¿ªÇÒ¿¡ ÁÖ¸ñÇÏ°í ½ÃÇàÇÑ cytochrome c ¹æÃâ ÃøÁ¤ ¹× ¹ÌÅäÄܵ帮¾Æ¸· ÀüÀ§ (¥Ä¥×m) ÃøÁ¤¿¡¼­ °øÈ÷ cytochrome c ¹æÃâ ¹× ¹ÌÅäÄܵ帮¾Æ¸· ÀüÀ§ (¥Ä¥×m)ÀÇ °¨¼Ò°¡ °üÂûµÇ¾ú´Ù.

°á·Ð: ÀÎü ´ëÀå¾Ï ¼¼Æ÷ÁÖ(HT-29)¿¡¼­ CDCA ÇÕ¼ºÀ¯µµÃ¼ÀÎ HS-1200À» ÀÌ¿ëÇÑ ¼¼Æ÷ Áõ½Ä¾ïÁ¦ ¹× ¼¼Æ÷ »ç¸Á ±âÀü ¿¬±¸¿¡¼­, ¾ÆÆ÷Åä½Ã½ºÀÇ À¯µµ°¡ HS-1200ÀÇ ¼¼Æ÷ »ç¸Á ±âÀü¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °ÍÀ» È®ÀÎÇÏ¿´´Ù. ÀÌ·¯ÇÑ ¾ÆÆ÷Åä½Ã½ºÀÇ À¯µµ¿¡´Â ¹ÌÅäÄܵ帮¾ÆÀÇ
¿ªÇÒÀÌ
Áß¿äÇÏ°Ô °ü·ÃµÇ´Â °ÍÀ¸·Î °üÂûµÇ¾ú´Ù. »ó±â °á°ú¸¦ Åä´ë·Î HS-1200ÀÇ Ç×¾Ï Ä¡·áÁ¦·Î¼­ÀÇ ¿ªÇÒ¿¡ °üÇÑ ±âÃÊ ÀÚ·á·Î¼­ÀÇ À¯¿ë¼ºÀ» Á¦½ÃÇÒ ¼ö ÀÖ¾ú´Ù.

Purpose: To investigate the growth inhibitory effects, and the underlying mechanism of human colon cancer cell (HT-29) death, induced by a new synthetic bile acid derivative (HS-1200).

Materials and Methods: Human colon cancer cells (HT-29), in exponential growth phase, were treated with various concentrations of a new synthetic bile acid derivative (HS-1200). The growth inhibitory effects on HT-29 cells were examined
using a
trypan blue exclusion assay. The extent of apoptosis was determined using agarose gel electrophoresis, TUNEL assays and Hoechst staining. The apoptotic cell death was also confirmed by Western blotting of PARP, caspase-3 and DNA fragmentation
factor
(DFF) analysis. To investigate the involvement of mitochondria, we employed immunofluorescent staining of cytochrome c and mitochondrial membrane potential analyses.

Results: The dose required for the half maximal inhibition (IC50) of the HT-29 cell growth was 100~150 §­ of HS-1200. Several changes, associated with the apoptosis of the HT-29 cells, were reveal by the agarose gel
eletrophoresis,
TUNEL assays and Hoechst staining, following their treatment with 100 §­ of HS-1200. HS-1200 treatment also induced caspase-3, PARP and DFF degradations, and the western blotting showed the processed caspase-3 p20, PARP p85 and DFF p30 and p11
cleaved
products. Mitochondrial events were also demonstrated. The cytochrome c staining indicated that cytochrome c had been released from the mitochondria in the HS-1200 treated cells. The mitochondrial membrane potential (¥Ä¥×m) was also
prominently decreased in the HS-1200 treated cells.

Conclusion: These findings suggest that the HS-1200 - induced apoptosis of human colon cancer cells (HT-29) is mediated via caspase and mitochondrial pathways.

Å°¿öµå

ÀÎü ´ëÀå¾Ï ¼¼Æ÷ÁÖ(HT-29); ´ãÁó»ê ÇÕ¼ºÀ¯µµÃ¼(HS-1200); ¾ÆÆ÷Åä½Ã½º; Bile acids; CDCA derivatives-induced apoptosis; Mitochondrial pathway;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS